Skip to main content
Erschienen in: Drug Safety 1/2000

01.01.2000 | Review Article

Drug-Induced Diarrhoea

verfasst von: Dr Olivier Chassany, Alessandra Michaux, Jean François Bergmann

Erschienen in: Drug Safety | Ausgabe 1/2000

Einloggen, um Zugang zu erhalten

Abstract

Diarrhoea is a relatively frequent adverse event, accounting for about 7% of all drug adverse effects. More than 700 drugs have been implicated in causing diarrhoea; those most frequently involved are antimicrobials, laxatives, magnesium-containing antacids, lactose- or sorbitol-containing products, nonsteroidal anti-inflammatory drugs, prostaglandins, colchicine, anti-neoplastics, antiarrhythmic drugs and cholinergic agents. Certain new drugs are likely to induce diarrhoea because of their pharmacodynamic properties; examples include anthraquinone-related agents, α-glucosidase inhibitors, lipase inhibitors and cholinesterase inhibitors. Antimicrobials are responsible for 25% of drug-induced diarrhoea. The disease spectrum of antimicrobial-associated diarrhoea ranges from benign diarrhoea to pseudomembranous colitis.
Several pathophysiological mechanisms are involved in drug-induced diarrhoea: osmotic diarrhoea, secretory diarrhoea, shortened transit time, exudative diarrhoea and protein-losing enteropathy, and malabsorption or maldigestion of fat and carbohydrates. Often 2 or more mechanisms are present simultaneously.
In clinical practice, 2 major types of diarrhoea are seen: acute diarrhoea, which usually appears during the first few days of treatment, and chronic diarrhoea, lasting more than 3 or 4 weeks and which can appear a long time after the start of drug therapy. Both can be severe and poorly tolerated.
In a patient presenting with diarrhoea, the medical history is very important, especially the drug history, as it can suggest a diagnosis of drug-induced diarrhoea and thereby avoid multiple diagnostic tests. The clinical examination should cover severity criteria such as fever, rectal emission of blood and mucus, dehydration and bodyweight loss. Establishing a relationship between drug consumption and diarrhoea or colitis can be difficult when the time elapsed between the start of the drug and the onset of symptoms is long, sometimes up to several months or years.
Literatur
1.
2.
Zurück zum Zitat Johnson RA. Adverse reactions in ten years’ general practice, computer-analysed. J R Soc Med 1986; 79: 143–6 Johnson RA. Adverse reactions in ten years’ general practice, computer-analysed. J R Soc Med 1986; 79: 143–6
3.
Zurück zum Zitat Beaugerie L, Gendre JP. Drug-induced colitis. Med Hyg 1993; 51: 2153–5 Beaugerie L, Gendre JP. Drug-induced colitis. Med Hyg 1993; 51: 2153–5
4.
Zurück zum Zitat Fine KD. Diarrhea. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors. Sleisenger and Fordtran’s gastrointestinal and liver disease: pathophysiology, diagnosis, management. 6th ed. Philadelphia: WB Saunders, 1998: 128-52 Fine KD. Diarrhea. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors. Sleisenger and Fordtran’s gastrointestinal and liver disease: pathophysiology, diagnosis, management. 6th ed. Philadelphia: WB Saunders, 1998: 128-52
6.
Zurück zum Zitat Pariente EA. Drug-induced enteropathies. Gastroenterol Clin Biol 1982; 6: 16–8PubMed Pariente EA. Drug-induced enteropathies. Gastroenterol Clin Biol 1982; 6: 16–8PubMed
7.
Zurück zum Zitat Ratnaike RN, Jones TE. Mechanisms of drug-induced diarrhoea in the elderly. Drugs Aging 1998; 13: 245–53PubMedCrossRef Ratnaike RN, Jones TE. Mechanisms of drug-induced diarrhoea in the elderly. Drugs Aging 1998; 13: 245–53PubMedCrossRef
8.
Zurück zum Zitat Longstreth GF, Newcomer AD. Drug-induced malabsorption. Mayo Clin Proc 1975; 50: 284–93PubMed Longstreth GF, Newcomer AD. Drug-induced malabsorption. Mayo Clin Proc 1975; 50: 284–93PubMed
9.
Zurück zum Zitat Riddell RH, Tanaka M, Mazzoleni G. Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: a case-control study. Gut 1992; 33: 683–6PubMedCrossRef Riddell RH, Tanaka M, Mazzoleni G. Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: a case-control study. Gut 1992; 33: 683–6PubMedCrossRef
10.
Zurück zum Zitat Giardiello FM, Hansen FC, Lazenby AJ, et al. Collagenous colitis setting of non steroidal anti-inflammatory drugs and antibiotics. Dig Dis Sci 1990; 35: 257–60PubMedCrossRef Giardiello FM, Hansen FC, Lazenby AJ, et al. Collagenous colitis setting of non steroidal anti-inflammatory drugs and antibiotics. Dig Dis Sci 1990; 35: 257–60PubMedCrossRef
11.
Zurück zum Zitat Beaugerie L, Luboinski J, Brousse N, et al. Drug-induced lymphocytic colitis. Gut 1994; 35: 426–8PubMedCrossRef Beaugerie L, Luboinski J, Brousse N, et al. Drug-induced lymphocytic colitis. Gut 1994; 35: 426–8PubMedCrossRef
12.
Zurück zum Zitat Duncan HD, Talbot IC, Silk DB. Collagenous colitis and cimetidine. Eur J Gastroenterol Hepatol 1997; 9: 819–20PubMedCrossRef Duncan HD, Talbot IC, Silk DB. Collagenous colitis and cimetidine. Eur J Gastroenterol Hepatol 1997; 9: 819–20PubMedCrossRef
13.
Zurück zum Zitat Berrebi D, Sautet A, Flejou JF, et al. Ticlopidine induced colitis: a histopathological study including apoptosis. J Clin Pathol 1998; 51: 280–3PubMedCrossRef Berrebi D, Sautet A, Flejou JF, et al. Ticlopidine induced colitis: a histopathological study including apoptosis. J Clin Pathol 1998; 51: 280–3PubMedCrossRef
14.
Zurück zum Zitat Yaziji N, Rassiat E, Michiels C, et al. Modopar-induced lymphocytic colitis. Ann Pathol 1996; 16: 25 Yaziji N, Rassiat E, Michiels C, et al. Modopar-induced lymphocytic colitis. Ann Pathol 1996; 16: 25
15.
Zurück zum Zitat Bouchet-Laneuw F, Deplaix P, Dumollard JM, et al. Chronic diarrhea secondary to tardyferon and associated to lymphocytic colitis. Gastroenterol Clin Biol 1997; 21: 83–4PubMed Bouchet-Laneuw F, Deplaix P, Dumollard JM, et al. Chronic diarrhea secondary to tardyferon and associated to lymphocytic colitis. Gastroenterol Clin Biol 1997; 21: 83–4PubMed
16.
Zurück zum Zitat Anttila VJ, Valtonen M. Carbamazepine-induced eosinophilic colitis. Epilepsia 1992; 33: 119–21PubMedCrossRef Anttila VJ, Valtonen M. Carbamazepine-induced eosinophilic colitis. Epilepsia 1992; 33: 119–21PubMedCrossRef
17.
Zurück zum Zitat Chagnon JP, Cerf M. Simvastatin-induced protein-losing enteropathy. Am J Gastroenterol 1992; 87: 257PubMed Chagnon JP, Cerf M. Simvastatin-induced protein-losing enteropathy. Am J Gastroenterol 1992; 87: 257PubMed
18.
Zurück zum Zitat Bo-Linn GW, Vendrell DD, Lee E, et al. An evaluation of the significance of microscopic colitis in patients with chronic diarrhea. J Clin Invest 1985; 75: 1559–69PubMedCrossRef Bo-Linn GW, Vendrell DD, Lee E, et al. An evaluation of the significance of microscopic colitis in patients with chronic diarrhea. J Clin Invest 1985; 75: 1559–69PubMedCrossRef
19.
Zurück zum Zitat Weber DJ, Tolkoff-Rubin NE, Rubin RH. Amoxicillin and potassium clavulanate: an antibiotic combination: mechanism of action, pharmacokinetics, antimicrobial spectrum, clinical efficacy and adverse effects. Pharmacotherapy 1984; 4: 122–36PubMed Weber DJ, Tolkoff-Rubin NE, Rubin RH. Amoxicillin and potassium clavulanate: an antibiotic combination: mechanism of action, pharmacokinetics, antimicrobial spectrum, clinical efficacy and adverse effects. Pharmacotherapy 1984; 4: 122–36PubMed
20.
Zurück zum Zitat Gales MA, Gales BJ. Recognition of severe cefixime-induced diarrhea. Clin Pharm 1993; 12: 881PubMed Gales MA, Gales BJ. Recognition of severe cefixime-induced diarrhea. Clin Pharm 1993; 12: 881PubMed
21.
Zurück zum Zitat Schwartzberg JE, Maresca RM, Remington JS. Gastrointestinal side effects associated with clindamycin. 1000 consecutive patients. Arch Intern Med 1976; 136: 876–9CrossRef Schwartzberg JE, Maresca RM, Remington JS. Gastrointestinal side effects associated with clindamycin. 1000 consecutive patients. Arch Intern Med 1976; 136: 876–9CrossRef
22.
Zurück zum Zitat Bauwens JE, McFarland LV, Melcher MJ, et al. Recurrent Clostridium difficile disease following ciprofloxacin use. Ann Pharmacother 1997; 31: 1090PubMed Bauwens JE, McFarland LV, Melcher MJ, et al. Recurrent Clostridium difficile disease following ciprofloxacin use. Ann Pharmacother 1997; 31: 1090PubMed
23.
Zurück zum Zitat Periti P, Mazzci T, Mini E, et al. Adverse effects of macrolide antibacterials. Drug Saf 1993; 9: 346–64PubMedCrossRef Periti P, Mazzci T, Mini E, et al. Adverse effects of macrolide antibacterials. Drug Saf 1993; 9: 346–64PubMedCrossRef
25.
Zurück zum Zitat Nord CE, Heimdahl A, Kager L. Antimicrobial induced alterations of the human oropharyngeal and intestinal microflora. Scand J Infect Dis 1986; 49Suppl.: 64–72 Nord CE, Heimdahl A, Kager L. Antimicrobial induced alterations of the human oropharyngeal and intestinal microflora. Scand J Infect Dis 1986; 49Suppl.: 64–72
26.
Zurück zum Zitat McFarland LV. Risk factors for antibiotic-associated diarrhea. Ann Med Interne 1998; 149: 261–6 McFarland LV. Risk factors for antibiotic-associated diarrhea. Ann Med Interne 1998; 149: 261–6
27.
Zurück zum Zitat Rao SSC, Edwards CA, Austen CJ, et al. Impaired colonic fermentation of carbohydrate after ampicillin. Gastroenterology 1988; 94: 928–32PubMed Rao SSC, Edwards CA, Austen CJ, et al. Impaired colonic fermentation of carbohydrate after ampicillin. Gastroenterology 1988; 94: 928–32PubMed
28.
Zurück zum Zitat Clausen MR, Bonnen H, Tvede M, et al. Colonic fermentation to short-chain fatty acids is decreased in antibiotic associated diarrhea. Gastroenterology 1991; 101: 1497–504PubMed Clausen MR, Bonnen H, Tvede M, et al. Colonic fermentation to short-chain fatty acids is decreased in antibiotic associated diarrhea. Gastroenterology 1991; 101: 1497–504PubMed
29.
Zurück zum Zitat Cerny A. Side effects and consequences of frequently used antibiotics in clinical practice. Schweiz Med Wochenschr 1996; 126: 528–34PubMed Cerny A. Side effects and consequences of frequently used antibiotics in clinical practice. Schweiz Med Wochenschr 1996; 126: 528–34PubMed
30.
Zurück zum Zitat Jaimes EC. Lincocinamides and the incidence of antibiotic-associated colitis. Clin Ther 1991; 13: 270–80PubMed Jaimes EC. Lincocinamides and the incidence of antibiotic-associated colitis. Clin Ther 1991; 13: 270–80PubMed
31.
32.
Zurück zum Zitat Moskovitz BL. Clinical adverse effects during ceftriaxone therapy. Am J Med 1984; 77(Suppl C): 84–8PubMed Moskovitz BL. Clinical adverse effects during ceftriaxone therapy. Am J Med 1984; 77(Suppl C): 84–8PubMed
33.
Zurück zum Zitat Job ML, Jacobs NF. Drug-induced Clostridium difficile-associated disease. Drug Saf 1997; 17: 37–46PubMedCrossRef Job ML, Jacobs NF. Drug-induced Clostridium difficile-associated disease. Drug Saf 1997; 17: 37–46PubMedCrossRef
34.
Zurück zum Zitat Pothoulakis C. Pathogenesis of Clostridium difficile-associated diarrhoea. Eur J Gastroenterol Hepatol 1996; 8: 1041–7PubMedCrossRef Pothoulakis C. Pathogenesis of Clostridium difficile-associated diarrhoea. Eur J Gastroenterol Hepatol 1996; 8: 1041–7PubMedCrossRef
35.
Zurück zum Zitat Rolfe RD, Finegold SM. Intestinal beta-lactamase activity in ampicillin-induced Clostridium difficile associated ileocolitis. J Infect Dis 1983; 147: 227–35PubMedCrossRef Rolfe RD, Finegold SM. Intestinal beta-lactamase activity in ampicillin-induced Clostridium difficile associated ileocolitis. J Infect Dis 1983; 147: 227–35PubMedCrossRef
36.
Zurück zum Zitat Tedesco FJ. Ampicillin-associated diarrhea. A prospective study. Am J Dig Dis 1975; 4: 295–7CrossRef Tedesco FJ. Ampicillin-associated diarrhea. A prospective study. Am J Dig Dis 1975; 4: 295–7CrossRef
37.
Zurück zum Zitat Toffler RB, Pingoud EG, Burrel MI. Acute colitis related to penicillin and penicillin derivatives. Lancet 1978; II: 707–9CrossRef Toffler RB, Pingoud EG, Burrel MI. Acute colitis related to penicillin and penicillin derivatives. Lancet 1978; II: 707–9CrossRef
38.
Zurück zum Zitat Werth B, Kobler E, Reinhart WH, et al. Clostridium difficile associated diarrhea in cephalosporin administration: experiences of the Swiss adverse drug reaction reporting system 1981-1995. Schweiz Med Wochenschr 1997; 89Suppl.: 5–8 Werth B, Kobler E, Reinhart WH, et al. Clostridium difficile associated diarrhea in cephalosporin administration: experiences of the Swiss adverse drug reaction reporting system 1981-1995. Schweiz Med Wochenschr 1997; 89Suppl.: 5–8
39.
Zurück zum Zitat Tedesco FJ, Barton RW, Alpers DH. Clindamycin associated colitis. Ann Intern Med 1974; 81: 429–33PubMed Tedesco FJ, Barton RW, Alpers DH. Clindamycin associated colitis. Ann Intern Med 1974; 81: 429–33PubMed
40.
Zurück zum Zitat Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol 1997; 92: 739–50PubMed Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol 1997; 92: 739–50PubMed
41.
Zurück zum Zitat Tabaqchali S, Jumaa P. Diagnosis and management of Clostridium difficile infection. BMJ 1995; 310: 1375–80PubMedCrossRef Tabaqchali S, Jumaa P. Diagnosis and management of Clostridium difficile infection. BMJ 1995; 310: 1375–80PubMedCrossRef
42.
Zurück zum Zitat Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995; 38: 350–4PubMedCrossRef Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995; 38: 350–4PubMedCrossRef
43.
Zurück zum Zitat Maignan M, Schuhmacher H, Pierfitte C, et al. Pseudo-membranous colitis associated with josamycin. Therapie 1994; 49: 461–2PubMed Maignan M, Schuhmacher H, Pierfitte C, et al. Pseudo-membranous colitis associated with josamycin. Therapie 1994; 49: 461–2PubMed
44.
Zurück zum Zitat Nawaz A, Mohammed I, Ahsan K, et al. Clostridium difficile colitis associated with treatment of Helicobacter pylori infection. Am J Gastroenterol 1998; 93: 1175–6PubMedCrossRef Nawaz A, Mohammed I, Ahsan K, et al. Clostridium difficile colitis associated with treatment of Helicobacter pylori infection. Am J Gastroenterol 1998; 93: 1175–6PubMedCrossRef
45.
Zurück zum Zitat McKinley M, Toffler RB. Antibiotic associated hemorragic colitis. Dig Dis Sci 1980; 25: 812–3PubMedCrossRef McKinley M, Toffler RB. Antibiotic associated hemorragic colitis. Dig Dis Sci 1980; 25: 812–3PubMedCrossRef
46.
Zurück zum Zitat Blanchi A, Pariente A. Acute hemorrhagic colitis after ingestion of amoxicillin. Gastroenterol Clin Biol 1992; 16: 1012–4PubMed Blanchi A, Pariente A. Acute hemorrhagic colitis after ingestion of amoxicillin. Gastroenterol Clin Biol 1992; 16: 1012–4PubMed
47.
Zurück zum Zitat Perez-Castrillon JL, Duenas A, Goyeneche MA, et al. Hemorrhagic colitis due to amoxicillin/clavulanate and nasal decongestants? J Clin Gastroenterol 1997; 25: 701PubMedCrossRef Perez-Castrillon JL, Duenas A, Goyeneche MA, et al. Hemorrhagic colitis due to amoxicillin/clavulanate and nasal decongestants? J Clin Gastroenterol 1997; 25: 701PubMedCrossRef
48.
Zurück zum Zitat Fort E, Sevestre C, Cahiez M, et al. Acute hemorrhagic colitis after oral ingestion of synergistin. Gastroenterol Clin Biol 1993; 17: 231–2PubMedCrossRef Fort E, Sevestre C, Cahiez M, et al. Acute hemorrhagic colitis after oral ingestion of synergistin. Gastroenterol Clin Biol 1993; 17: 231–2PubMedCrossRef
49.
Zurück zum Zitat Decaux C, Devroede G. Acute colitis related to spiramycin. Lancet 1978; II: 993CrossRef Decaux C, Devroede G. Acute colitis related to spiramycin. Lancet 1978; II: 993CrossRef
50.
Zurück zum Zitat David XR, Pierrugues R, Michel H. Acute hemorrhagic colitis related to oral administration of cephalosporin. Gastroenterol Clin Biol 1991; 15: 659PubMed David XR, Pierrugues R, Michel H. Acute hemorrhagic colitis related to oral administration of cephalosporin. Gastroenterol Clin Biol 1991; 15: 659PubMed
51.
Zurück zum Zitat Bellaiche G, Le Pennec MP, Choudat L, et al. Value of rectosigmoidoscopy with bacteriological culture of colonic biopsies in the diagnosis of post-antibiotic hemorrhagic colitis related to Klebsiella oxytoca. Gastroenterol Clin Biol 1997; 21: 764–7PubMed Bellaiche G, Le Pennec MP, Choudat L, et al. Value of rectosigmoidoscopy with bacteriological culture of colonic biopsies in the diagnosis of post-antibiotic hemorrhagic colitis related to Klebsiella oxytoca. Gastroenterol Clin Biol 1997; 21: 764–7PubMed
52.
Zurück zum Zitat Benoit R, Danchequin Dorval E, Loulergue J, et al. Post-antibiotic diarrheas: role of Klebsiella oxytoca. Gastroenterol Clin Biol 1992; 16: 860–4PubMed Benoit R, Danchequin Dorval E, Loulergue J, et al. Post-antibiotic diarrheas: role of Klebsiella oxytoca. Gastroenterol Clin Biol 1992; 16: 860–4PubMed
53.
Zurück zum Zitat Cleau D, humblot S, Jobard JM, et al. Acute right side hemorrhagic colitis with demonstration of Klebsiella oxytoca after treatment with amoxicillin. Presse Med 1994; 23: 1879–80PubMed Cleau D, humblot S, Jobard JM, et al. Acute right side hemorrhagic colitis with demonstration of Klebsiella oxytoca after treatment with amoxicillin. Presse Med 1994; 23: 1879–80PubMed
54.
Zurück zum Zitat Danna PL, Urban C, Bellin E, et al. Role of Candida in pathogenesis of antibiotic-associated diarrhea in elderly inpatients. Lancet 1991; 337: 511–4PubMedCrossRef Danna PL, Urban C, Bellin E, et al. Role of Candida in pathogenesis of antibiotic-associated diarrhea in elderly inpatients. Lancet 1991; 337: 511–4PubMedCrossRef
55.
Zurück zum Zitat Dobbins WO, Herrero BA, Mansbach DM. Morphologic alterations associated with neomycin induced malabsorption. Am J Med Sci 1968; 255: 63–7PubMedCrossRef Dobbins WO, Herrero BA, Mansbach DM. Morphologic alterations associated with neomycin induced malabsorption. Am J Med Sci 1968; 255: 63–7PubMedCrossRef
56.
Zurück zum Zitat Giannella RA, Serumaga J, Walls D, et al. Effect of clindamycin on intestinal water and glucose transport in the rat. Gastroenterology 1981; 80: 907–13PubMed Giannella RA, Serumaga J, Walls D, et al. Effect of clindamycin on intestinal water and glucose transport in the rat. Gastroenterology 1981; 80: 907–13PubMed
57.
Zurück zum Zitat Weber FH, Richards RD, McCallum RW. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol 1993; 88: 485–90PubMed Weber FH, Richards RD, McCallum RW. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol 1993; 88: 485–90PubMed
58.
Zurück zum Zitat Lees GM, Percy WH. Antibiotic associated colitis: an in vitro investigation of the effects of antibiotics on intestinal motility. Br J Pharmacol 1981; 73: 535–47PubMedCrossRef Lees GM, Percy WH. Antibiotic associated colitis: an in vitro investigation of the effects of antibiotics on intestinal motility. Br J Pharmacol 1981; 73: 535–47PubMedCrossRef
59.
Zurück zum Zitat Lehtola J, Jaunohen P, Kesaniemi A, et al. Effect of erythromycin on the oro-caecal transit time in man. Eur J Clin Pharmacol 1990; 39: 555–8PubMedCrossRef Lehtola J, Jaunohen P, Kesaniemi A, et al. Effect of erythromycin on the oro-caecal transit time in man. Eur J Clin Pharmacol 1990; 39: 555–8PubMedCrossRef
60.
Zurück zum Zitat Tomosa S, Kuroume T, Arai H, et al. Erythromycin induces migrating motor complex in human gastrointestinal tract. Dig Dis Sci 1986; 31: 157–61CrossRef Tomosa S, Kuroume T, Arai H, et al. Erythromycin induces migrating motor complex in human gastrointestinal tract. Dig Dis Sci 1986; 31: 157–61CrossRef
61.
Zurück zum Zitat Bjarnason J, MacPherson A. The changing gastrointestinal side effect profile of non steroidal anti-inflammatory drugs. A new approach for the prevention of a new problem. Scand J Gastroenterol 1989; 24: 56–64CrossRef Bjarnason J, MacPherson A. The changing gastrointestinal side effect profile of non steroidal anti-inflammatory drugs. A new approach for the prevention of a new problem. Scand J Gastroenterol 1989; 24: 56–64CrossRef
62.
Zurück zum Zitat Davies NM, Can PD. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Dis Colon Rectum 1995; 38: 1311–21PubMedCrossRef Davies NM, Can PD. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Dis Colon Rectum 1995; 38: 1311–21PubMedCrossRef
63.
Zurück zum Zitat Morgan GJ, Poland M, DeLapp RE. Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly. Am J Med 1993; 95Suppl. 2A: 19–27CrossRef Morgan GJ, Poland M, DeLapp RE. Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly. Am J Med 1993; 95Suppl. 2A: 19–27CrossRef
64.
Zurück zum Zitat Bjarnason I, Williams P, Smethurst P, et al. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 1986; 27: 1292–7PubMedCrossRef Bjarnason I, Williams P, Smethurst P, et al. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 1986; 27: 1292–7PubMedCrossRef
65.
Zurück zum Zitat Arvanitakis C, Chen GH, Folscroft J, et al. Effects of aspirin on intestinal absorption of glucose, Na and water in man. Gut 1977; 18: 187–90PubMedCrossRef Arvanitakis C, Chen GH, Folscroft J, et al. Effects of aspirin on intestinal absorption of glucose, Na and water in man. Gut 1977; 18: 187–90PubMedCrossRef
66.
Zurück zum Zitat Lapoile E, Bellaiche G, Nouts A, et al. Pseudomembranous colitis after ingestion of diclofenac. Gastroenterol Clin Biol 1988, 22: 100–1 Lapoile E, Bellaiche G, Nouts A, et al. Pseudomembranous colitis after ingestion of diclofenac. Gastroenterol Clin Biol 1988, 22: 100–1
67.
68.
Zurück zum Zitat Kwo PY, Tremaine WJ. Nonsteroidal anti-inflammatory druginduced enteropathy: case discussion and review of the literature. Mayo Clin Proc 1995; 70: 55–61PubMed Kwo PY, Tremaine WJ. Nonsteroidal anti-inflammatory druginduced enteropathy: case discussion and review of the literature. Mayo Clin Proc 1995; 70: 55–61PubMed
69.
Zurück zum Zitat Bjarnason I, Prouse P, Smith T, et al. Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet 1987; II: 711–4CrossRef Bjarnason I, Prouse P, Smith T, et al. Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet 1987; II: 711–4CrossRef
70.
Zurück zum Zitat Hall RI, Petty AH, Cobden I, et al. Enteritis and colitis associated with mefenamic acid. BMJ 1983; 287: 1182PubMedCrossRef Hall RI, Petty AH, Cobden I, et al. Enteritis and colitis associated with mefenamic acid. BMJ 1983; 287: 1182PubMedCrossRef
71.
Zurück zum Zitat Gibson GR, Withacre EB, Ricotti CA. Colitis induced by non-steroidal anti-inflammatory drugs. Arch Intern Med 1992; 152: 625–32PubMedCrossRef Gibson GR, Withacre EB, Ricotti CA. Colitis induced by non-steroidal anti-inflammatory drugs. Arch Intern Med 1992; 152: 625–32PubMedCrossRef
72.
Zurück zum Zitat Dao T, Grimaux-Jardin I, Fellous F, et al. Ulcerative colitis secondary to the ingestion of lysine acetylsalicylate. Gastroenterol Clin Biol 1993; 17: 66–7PubMed Dao T, Grimaux-Jardin I, Fellous F, et al. Ulcerative colitis secondary to the ingestion of lysine acetylsalicylate. Gastroenterol Clin Biol 1993; 17: 66–7PubMed
73.
Zurück zum Zitat Sturges HF, Krone CL. Ulceration and stricture of the jejunum in a patient on long-term indomethacin therapy. Am J Gastroenterol 1973; 59: 162–9PubMed Sturges HF, Krone CL. Ulceration and stricture of the jejunum in a patient on long-term indomethacin therapy. Am J Gastroenterol 1973; 59: 162–9PubMed
74.
Zurück zum Zitat Langmann MJS, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. BMJ 1985; 290: 347–9CrossRef Langmann MJS, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. BMJ 1985; 290: 347–9CrossRef
75.
Zurück zum Zitat Bjarnason I, MacPherson AJS. Intestinal toxicity of non-steroidal anti-inflammatory drugs. Pharmacol Ther 1994; 62: 145–57PubMedCrossRef Bjarnason I, MacPherson AJS. Intestinal toxicity of non-steroidal anti-inflammatory drugs. Pharmacol Ther 1994; 62: 145–57PubMedCrossRef
76.
Zurück zum Zitat Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987; 107: 513–6PubMed Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987; 107: 513–6PubMed
77.
Zurück zum Zitat Wilson RG, Smith AN, McIntyre IMC. Complications of diverticular disease and non-steroidal anti-inflammatory drugs: a prospective study. Br J Surg 1990; 77: 1103–4PubMedCrossRef Wilson RG, Smith AN, McIntyre IMC. Complications of diverticular disease and non-steroidal anti-inflammatory drugs: a prospective study. Br J Surg 1990; 77: 1103–4PubMedCrossRef
78.
Zurück zum Zitat Fang WF, Broughton A, Jacobson ED. Indomethacin-induced intestinal inflammation. Am J Dig Dis 1977; 22: 749–60PubMedCrossRef Fang WF, Broughton A, Jacobson ED. Indomethacin-induced intestinal inflammation. Am J Dig Dis 1977; 22: 749–60PubMedCrossRef
79.
Zurück zum Zitat Rutherford D, Stockdill G, Hamer-Hodges DW, et al. Proctocolitis induced by salicylate. BMJ 1984; 288: 794PubMedCrossRef Rutherford D, Stockdill G, Hamer-Hodges DW, et al. Proctocolitis induced by salicylate. BMJ 1984; 288: 794PubMedCrossRef
80.
Zurück zum Zitat Chakraborty TK, Bhatia D, Heading RC, et al. Salicylate induced exacerbation of ulcerative colitis. Gut 1987; 28: 613–5PubMedCrossRef Chakraborty TK, Bhatia D, Heading RC, et al. Salicylate induced exacerbation of ulcerative colitis. Gut 1987; 28: 613–5PubMedCrossRef
81.
Zurück zum Zitat Barnejee AK. Enteropathy induced by non-steroidal anti-inflammatory drugs often subclinical but may mimic Crohn’s disease. BMJ 1989; 298: 1539–40CrossRef Barnejee AK. Enteropathy induced by non-steroidal anti-inflammatory drugs often subclinical but may mimic Crohn’s disease. BMJ 1989; 298: 1539–40CrossRef
82.
Zurück zum Zitat Bridges AJ, Marshall JB, Diaz-Arias AA, et al. Acute eosinophilic colitis and hypersensitivity reaction associated with naproxen therapy. Am J Med 1990; 89: 526–7PubMedCrossRef Bridges AJ, Marshall JB, Diaz-Arias AA, et al. Acute eosinophilic colitis and hypersensitivity reaction associated with naproxen therapy. Am J Med 1990; 89: 526–7PubMedCrossRef
83.
Zurück zum Zitat Guedon C, Bruna T, Ducrotte P, et al. Severe diarrhea caused by Ticlid associated with disorders of small intestine motility. Gastroenterol Clin Biol 1989; 13: 934–7PubMed Guedon C, Bruna T, Ducrotte P, et al. Severe diarrhea caused by Ticlid associated with disorders of small intestine motility. Gastroenterol Clin Biol 1989; 13: 934–7PubMed
84.
Zurück zum Zitat Giardina MG, Matarazzo M, Cacciatore L, et al. Ticlopidine can cause chronic diarrhea. Lancet 1984; I: 407CrossRef Giardina MG, Matarazzo M, Cacciatore L, et al. Ticlopidine can cause chronic diarrhea. Lancet 1984; I: 407CrossRef
85.
Zurück zum Zitat Chassany O, Bacq Y, Metman EH, et al. Severe chronic diarrhea during treatment with ticlopidine. Gastroenterol Clin Biol 1989; 13: 950PubMed Chassany O, Bacq Y, Metman EH, et al. Severe chronic diarrhea during treatment with ticlopidine. Gastroenterol Clin Biol 1989; 13: 950PubMed
86.
Zurück zum Zitat Fraga MD, Garcia B, Agud JL, et al. Severe chronic diarrhea induced by ticlopidine. Ann Pharmacother 1996; 30: 1496PubMed Fraga MD, Garcia B, Agud JL, et al. Severe chronic diarrhea induced by ticlopidine. Ann Pharmacother 1996; 30: 1496PubMed
87.
Zurück zum Zitat Mansoor GA, Aziz K. Delayed chronic diarrhea and weight loss possibly due to ticlopidine therapy. Ann Pharmacother 1997; 31: 870–2PubMed Mansoor GA, Aziz K. Delayed chronic diarrhea and weight loss possibly due to ticlopidine therapy. Ann Pharmacother 1997; 31: 870–2PubMed
88.
Zurück zum Zitat Ruget O, Burtin P, Cerz H, et al. Chronic diarrhea associated with villous atrophy and lymphocytic gastritis caused by ticlopidine. Gastroenterol Clin Biol 1992; 16: 290PubMed Ruget O, Burtin P, Cerz H, et al. Chronic diarrhea associated with villous atrophy and lymphocytic gastritis caused by ticlopidine. Gastroenterol Clin Biol 1992; 16: 290PubMed
89.
Zurück zum Zitat Swine C, Cornette P, Van Pee D, et al. Ticlopidine, diarrhea and lymphocytic colitis. Gastroenterol Clin Biol 1998; 22: 475–6PubMed Swine C, Cornette P, Van Pee D, et al. Ticlopidine, diarrhea and lymphocytic colitis. Gastroenterol Clin Biol 1998; 22: 475–6PubMed
90.
Zurück zum Zitat Brigot C, Courillon-Mallet A, Roucayrol AM, et al. Lymphocytic colitis and ticlopidine. Gastroenterol Clin Biol 1998; 22: 361–2PubMed Brigot C, Courillon-Mallet A, Roucayrol AM, et al. Lymphocytic colitis and ticlopidine. Gastroenterol Clin Biol 1998; 22: 361–2PubMed
91.
Zurück zum Zitat Martinez Aviles P, Gisbert-Moya C, Berbegal-Serra J, et al. Ticlopidine-induced lymphocytic colitis. Med Clin Barc 1996; 106: 307 Martinez Aviles P, Gisbert-Moya C, Berbegal-Serra J, et al. Ticlopidine-induced lymphocytic colitis. Med Clin Barc 1996; 106: 307
92.
Zurück zum Zitat Cohen IS, Jick H, Cohen SI, et al. Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program. Prog Cardiovasc Dis 1977; 20: 152–63CrossRef Cohen IS, Jick H, Cohen SI, et al. Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program. Prog Cardiovasc Dis 1977; 20: 152–63CrossRef
93.
Zurück zum Zitat Auricchio RJ. Cardiac arrhythmias. In: Young LY, Koda-Kimble MA, editors. Applied therapeutics: the clinical use of drugs, 4th ed. Vancouver: Applied Therapeutics, 1988 Auricchio RJ. Cardiac arrhythmias. In: Young LY, Koda-Kimble MA, editors. Applied therapeutics: the clinical use of drugs, 4th ed. Vancouver: Applied Therapeutics, 1988
94.
Zurück zum Zitat Romankiewicz JA, Reidenberg M, Drayer D, et al. The noninterference of aluminium hydroxide gel with quinidine sulphate absorption: an approach to control quinidine-induced diarrhea. Am Heart J 1978; 96: 518–20PubMedCrossRef Romankiewicz JA, Reidenberg M, Drayer D, et al. The noninterference of aluminium hydroxide gel with quinidine sulphate absorption: an approach to control quinidine-induced diarrhea. Am Heart J 1978; 96: 518–20PubMedCrossRef
95.
Zurück zum Zitat Rudusky BM. Cholestyramine therapy for quinidine-induced diarrhea. Case reports. Angiology 1997; 48: 173–6PubMedCrossRef Rudusky BM. Cholestyramine therapy for quinidine-induced diarrhea. Case reports. Angiology 1997; 48: 173–6PubMedCrossRef
96.
Zurück zum Zitat Horvath F, Marbury TC, Uhlemann ER, et al. Severe diarrhea secondary to propranolol. South Med 1979; 72: 367–8CrossRef Horvath F, Marbury TC, Uhlemann ER, et al. Severe diarrhea secondary to propranolol. South Med 1979; 72: 367–8CrossRef
97.
Zurück zum Zitat Robinson JD, Burtner DE. Severe diarrhea secondary to propranolol. Drug Intell Clin Pharm 1981; 15: 49–50PubMed Robinson JD, Burtner DE. Severe diarrhea secondary to propranolol. Drug Intell Clin Pharm 1981; 15: 49–50PubMed
98.
Zurück zum Zitat Rolachon A, Bichard P, Kezachian G, et al. Chronic diarrhea caused by isradipine. Gastroenterol Clin Biol 1993; 17: 310–1PubMed Rolachon A, Bichard P, Kezachian G, et al. Chronic diarrhea caused by isradipine. Gastroenterol Clin Biol 1993; 17: 310–1PubMed
99.
Zurück zum Zitat Hedner T. Calcium channel blockers: spectrum of side effects and drug interactions. Acta Pharmacol Toxicol 1986; 58Suppl. 2: 119–30 Hedner T. Calcium channel blockers: spectrum of side effects and drug interactions. Acta Pharmacol Toxicol 1986; 58Suppl. 2: 119–30
100.
Zurück zum Zitat Quart BD, Guglielmo BJ. Prolonged diarrhea secondary to methyldopa therapy. Drug Intell Clin Pharm 1983; 17: 462PubMed Quart BD, Guglielmo BJ. Prolonged diarrhea secondary to methyldopa therapy. Drug Intell Clin Pharm 1983; 17: 462PubMed
101.
Zurück zum Zitat Gloth FM, Busby MJ. Methyldopa-induced diarrhea: case of iatrogenic diarrhea leading to request for nursing home replacement. Am J Med 1989; 87: 480–1PubMedCrossRef Gloth FM, Busby MJ. Methyldopa-induced diarrhea: case of iatrogenic diarrhea leading to request for nursing home replacement. Am J Med 1989; 87: 480–1PubMedCrossRef
102.
Zurück zum Zitat Graham CF, Gallagher K, Jones JK. Acute colitis with methyldopa. N Engl J Med 1981; 304: 1044–5PubMed Graham CF, Gallagher K, Jones JK. Acute colitis with methyldopa. N Engl J Med 1981; 304: 1044–5PubMed
103.
Zurück zum Zitat Shneerson JM, Gazzard BJ. Reversible malabsorption caused by methyldopa. BMJ 1977; 2: 1456–7PubMedCrossRef Shneerson JM, Gazzard BJ. Reversible malabsorption caused by methyldopa. BMJ 1977; 2: 1456–7PubMedCrossRef
104.
Zurück zum Zitat Mahdyoon H, Battilana G, Rosman H, et al. The evolving pattern of digoxin intoxication: observations at a large urban hospital from 1980-1988. Am Heart J 1990; 120: 1189–94PubMedCrossRef Mahdyoon H, Battilana G, Rosman H, et al. The evolving pattern of digoxin intoxication: observations at a large urban hospital from 1980-1988. Am Heart J 1990; 120: 1189–94PubMedCrossRef
105.
106.
Zurück zum Zitat Bourhis T, Riard P, Danel V, et al. Digitalis poisoning with severe ischemic colitis: a favorable course after treatment with specific antibodies. Gastroenterol Clin Biol 1990; 14: 95PubMed Bourhis T, Riard P, Danel V, et al. Digitalis poisoning with severe ischemic colitis: a favorable course after treatment with specific antibodies. Gastroenterol Clin Biol 1990; 14: 95PubMed
107.
Zurück zum Zitat Bouaniche M, Chassagne P, Landrin I, et al. Lymphocytic colitis caused by Cyclo 3 Fort. Rev Med Int 1996; 17: 776–8CrossRef Bouaniche M, Chassagne P, Landrin I, et al. Lymphocytic colitis caused by Cyclo 3 Fort. Rev Med Int 1996; 17: 776–8CrossRef
108.
Zurück zum Zitat Thomas-Anterion C, Guy C, Vial F, et al. Unexplained chronic diarrhea. A propos of 4 new cases under Cyclo 3 Fort and review of the literature. Rev Med Interne 1993; 14: 215–7PubMedCrossRef Thomas-Anterion C, Guy C, Vial F, et al. Unexplained chronic diarrhea. A propos of 4 new cases under Cyclo 3 Fort and review of the literature. Rev Med Interne 1993; 14: 215–7PubMedCrossRef
109.
Zurück zum Zitat Ouyahya F, Codjovi P, Machet MC, et al. Diarrhea induced by Cyclo 3 Fort and lymphocytic colitis. Gastroenterol Clin Biol 1993; 17: 65–6PubMed Ouyahya F, Codjovi P, Machet MC, et al. Diarrhea induced by Cyclo 3 Fort and lymphocytic colitis. Gastroenterol Clin Biol 1993; 17: 65–6PubMed
110.
Zurück zum Zitat Pierrugues R, Saingra B. Lymphocytic colitis and Cyclo 3 Fort: 4 new cases. Gastroenterol Clin Biol 1996; 20: 916–7PubMed Pierrugues R, Saingra B. Lymphocytic colitis and Cyclo 3 Fort: 4 new cases. Gastroenterol Clin Biol 1996; 20: 916–7PubMed
111.
Zurück zum Zitat Maechel H. Cirkan-induced chronic diarrhea. Gastroenterol Clin Biol 1992; 16: 373PubMed Maechel H. Cirkan-induced chronic diarrhea. Gastroenterol Clin Biol 1992; 16: 373PubMed
112.
Zurück zum Zitat Raoul JL, Dautreme S, Heresbach N, et al. Chronic diarrhea during treatment with Veinotonyl 75. Ann Gastroenterol Hepatol 1994; 30: 25 Raoul JL, Dautreme S, Heresbach N, et al. Chronic diarrhea during treatment with Veinotonyl 75. Ann Gastroenterol Hepatol 1994; 30: 25
113.
Zurück zum Zitat Hastier P, Bianchi D, Chichmanian RM, et al. Chronic diarrhea secondary to Veinamitol. Therapie 1994; 49: 148–9PubMed Hastier P, Bianchi D, Chichmanian RM, et al. Chronic diarrhea secondary to Veinamitol. Therapie 1994; 49: 148–9PubMed
114.
Zurück zum Zitat Widgren S, de Peyer R, Geissbuhler P, et al. Enterocolitis due to a saponin-containing drug. A propos of a case. Schweiz Med Wochenschr 1994; 124: 313–8PubMed Widgren S, de Peyer R, Geissbuhler P, et al. Enterocolitis due to a saponin-containing drug. A propos of a case. Schweiz Med Wochenschr 1994; 124: 313–8PubMed
115.
Zurück zum Zitat Piper DW. A comparative overview of the adverse effects of antiulcer drugs. Drug Saf 1995; 12: 120–38PubMedCrossRef Piper DW. A comparative overview of the adverse effects of antiulcer drugs. Drug Saf 1995; 12: 120–38PubMedCrossRef
116.
Zurück zum Zitat Yen L. Cimetidine-induced diarrhea. Drug Intell Clin Pharm 1985; 19: 185 Yen L. Cimetidine-induced diarrhea. Drug Intell Clin Pharm 1985; 19: 185
117.
Zurück zum Zitat Beaugerie L, Patey N, Brousse N. Ranitidine, diarrhea, and lymphocytic colitis. Gut 1995; 37: 708–11PubMedCrossRef Beaugerie L, Patey N, Brousse N. Ranitidine, diarrhea, and lymphocytic colitis. Gut 1995; 37: 708–11PubMedCrossRef
118.
Zurück zum Zitat Beaugerie L, Berrebi D, Dikov D, et al. Epithelial apoptosis a very early marker of drug-induced colitis. The example of ranitidine. Gastroenterol Clin Biol 1996; 20: 918–9 Beaugerie L, Berrebi D, Dikov D, et al. Epithelial apoptosis a very early marker of drug-induced colitis. The example of ranitidine. Gastroenterol Clin Biol 1996; 20: 918–9
119.
Zurück zum Zitat Duncan HD, Talbot IC, Silk DB. Collagenous colitis and cimetidine. Eur J Gastroenterol Hepatol 1997; 9: 819–20PubMedCrossRef Duncan HD, Talbot IC, Silk DB. Collagenous colitis and cimetidine. Eur J Gastroenterol Hepatol 1997; 9: 819–20PubMedCrossRef
120.
Zurück zum Zitat Field R, Meyer GW. Diarrhea from cimetidine. N Engl J Med 1978; 299: 262PubMed Field R, Meyer GW. Diarrhea from cimetidine. N Engl J Med 1978; 299: 262PubMed
121.
Zurück zum Zitat Leufkens H, Claessens A, Heerdink E, et al. A prospective follow-up study of 5669 users of lansoprazole in daily practice. Aliment Pharmacol Ther 1997; 11: 887–97PubMedCrossRef Leufkens H, Claessens A, Heerdink E, et al. A prospective follow-up study of 5669 users of lansoprazole in daily practice. Aliment Pharmacol Ther 1997; 11: 887–97PubMedCrossRef
123.
Zurück zum Zitat Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995; 123: 241–9PubMed Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995; 123: 241–9PubMed
124.
Zurück zum Zitat Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993; 119: 257–62PubMed Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993; 119: 257–62PubMed
125.
Zurück zum Zitat Herting RL, Clay GA. Overview of clinical safety with misoprostol. Dig Dis Sci 1985; 30Suppl.: 185S–93SPubMedCrossRef Herting RL, Clay GA. Overview of clinical safety with misoprostol. Dig Dis Sci 1985; 30Suppl.: 185S–93SPubMedCrossRef
126.
Zurück zum Zitat Bocanegra TS, Weaver AL, Tindall EA, et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec osteoarthritis study group. J Rheumatol 1998; 25: 1602–11PubMed Bocanegra TS, Weaver AL, Tindall EA, et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec osteoarthritis study group. J Rheumatol 1998; 25: 1602–11PubMed
127.
128.
Zurück zum Zitat Davis R, Yarker YE, Goa KL. Diclofenac/misoprostol: a review of its pharmacology and therapeutic efficacy in painful inflammatory conditions. Drugs Aging 1995; 7: 372–93PubMedCrossRef Davis R, Yarker YE, Goa KL. Diclofenac/misoprostol: a review of its pharmacology and therapeutic efficacy in painful inflammatory conditions. Drugs Aging 1995; 7: 372–93PubMedCrossRef
129.
Zurück zum Zitat Melo Gomes JA, Roth SH, Zeeh J, et al. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993; 52: 881–5PubMedCrossRef Melo Gomes JA, Roth SH, Zeeh J, et al. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993; 52: 881–5PubMedCrossRef
130.
Zurück zum Zitat Bright-Asare P. Treatment of duodenal ulcer with enprostil, a prostaglandin E2 analog. Am J Med 1986; 81: 64–8PubMedCrossRef Bright-Asare P. Treatment of duodenal ulcer with enprostil, a prostaglandin E2 analog. Am J Med 1986; 81: 64–8PubMedCrossRef
131.
Zurück zum Zitat Jain JK, Mishell DR. A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second-trimester pregnancy. N Engl J Med 1994; 331: 290–3PubMedCrossRef Jain JK, Mishell DR. A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second-trimester pregnancy. N Engl J Med 1994; 331: 290–3PubMedCrossRef
132.
Zurück zum Zitat Castell DO, Sigmund C, Patterson D, et al. Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 investigator group. Am J Gastroenterol 1998; 93: 547–52PubMedCrossRef Castell DO, Sigmund C, Patterson D, et al. Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 investigator group. Am J Gastroenterol 1998; 93: 547–52PubMedCrossRef
133.
Zurück zum Zitat Wiseman LR, Faulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994; 47: 116–52PubMedCrossRef Wiseman LR, Faulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994; 47: 116–52PubMedCrossRef
134.
Zurück zum Zitat Nguyen M, Dougados M, Berdah L, et al. Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum 1994; 37: 529–36PubMedCrossRef Nguyen M, Dougados M, Berdah L, et al. Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum 1994; 37: 529–36PubMedCrossRef
135.
Zurück zum Zitat Blondon H, Bikart I, Bergmann JF. Severe diarrhea with hypokalemia attributed to diacetylrhein. Gastroenterol Clin Biol 1995; 19: 851–2PubMed Blondon H, Bikart I, Bergmann JF. Severe diarrhea with hypokalemia attributed to diacetylrhein. Gastroenterol Clin Biol 1995; 19: 851–2PubMed
136.
Zurück zum Zitat Verne GN, Eaker EY, Davis RH, et al. Colchicine is an effective treatment for patients with chronic constipation: an openlabel trial. Dig Dis Sci 1997; 42: 1959–63PubMedCrossRef Verne GN, Eaker EY, Davis RH, et al. Colchicine is an effective treatment for patients with chronic constipation: an openlabel trial. Dig Dis Sci 1997; 42: 1959–63PubMedCrossRef
137.
Zurück zum Zitat Ehrenfeld M, Levy M, Sharon P, et al. Gastrointestinal effects of long-term colchicine therapy in patients with recurrent polyserositis (familial Mediterranean fever). Dig Dis Sci 1982; 27: 723–7PubMedCrossRef Ehrenfeld M, Levy M, Sharon P, et al. Gastrointestinal effects of long-term colchicine therapy in patients with recurrent polyserositis (familial Mediterranean fever). Dig Dis Sci 1982; 27: 723–7PubMedCrossRef
138.
Zurück zum Zitat Fradkin A, Yahav J, Zemer D, et al. Colchicine-induced lactose malabsorption in patients with familial Mediterranean fever. Isr J Med Sci 1995; 31: 616–20PubMed Fradkin A, Yahav J, Zemer D, et al. Colchicine-induced lactose malabsorption in patients with familial Mediterranean fever. Isr J Med Sci 1995; 31: 616–20PubMed
139.
140.
Zurück zum Zitat Furst DE. Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritis. Pharmacotherapy 1983; 3: 284–98PubMed Furst DE. Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritis. Pharmacotherapy 1983; 3: 284–98PubMed
141.
Zurück zum Zitat Wallin BA, McCafferty JP, Fox MJ, et al. Incidence and management of diarrhea during long term auranofin therapy. J Rheumatol 1988; 15: 1755–8PubMed Wallin BA, McCafferty JP, Fox MJ, et al. Incidence and management of diarrhea during long term auranofin therapy. J Rheumatol 1988; 15: 1755–8PubMed
142.
Zurück zum Zitat Magaro M, Altomonte L, Mirone L, et al. Effect of oral gold salt therapy on bile acid absorption in rheumatoid arthritis patients. Clin Rheumatol 1990; 9: 42–7PubMedCrossRef Magaro M, Altomonte L, Mirone L, et al. Effect of oral gold salt therapy on bile acid absorption in rheumatoid arthritis patients. Clin Rheumatol 1990; 9: 42–7PubMedCrossRef
143.
Zurück zum Zitat Gerster JC, Kalbermatten A, Peyer R, et al. Toxic reactions to gold salts with severe enterocolitis in a patient with rheumatoid arthritis. Schweiz Med Wochenschr 1976; 106: 1606–8PubMed Gerster JC, Kalbermatten A, Peyer R, et al. Toxic reactions to gold salts with severe enterocolitis in a patient with rheumatoid arthritis. Schweiz Med Wochenschr 1976; 106: 1606–8PubMed
144.
Zurück zum Zitat Jackson CW, Haboubi NY, Whorwell PJ, et al. Gold induced enterocolitis. Gut 1986; 27: 452–6PubMedCrossRef Jackson CW, Haboubi NY, Whorwell PJ, et al. Gold induced enterocolitis. Gut 1986; 27: 452–6PubMedCrossRef
145.
Zurück zum Zitat Bross-Bach U, Saal JG, Hartmann F, et al. Ulcerative colitis caused by oral gold therapy in rheumatoid arthritis. Z Rheumatol 1987; 46: 201–4PubMed Bross-Bach U, Saal JG, Hartmann F, et al. Ulcerative colitis caused by oral gold therapy in rheumatoid arthritis. Z Rheumatol 1987; 46: 201–4PubMed
146.
Zurück zum Zitat Marcuard SP, Ehrinpreis MN, Fitter WF. Gold induced ulcerative proctitis: report and review of the literature. J Rheumatol 1987; 14: 142–4PubMed Marcuard SP, Ehrinpreis MN, Fitter WF. Gold induced ulcerative proctitis: report and review of the literature. J Rheumatol 1987; 14: 142–4PubMed
147.
Zurück zum Zitat Evron E, Brautbar C, Becker S, et al. Correlation between goldinduced enterocolitis and the presence of the HLADRB1* 0404 allele. Arthritis Rheum 1995; 38: 755–9PubMedCrossRef Evron E, Brautbar C, Becker S, et al. Correlation between goldinduced enterocolitis and the presence of the HLADRB1* 0404 allele. Arthritis Rheum 1995; 38: 755–9PubMedCrossRef
148.
149.
Zurück zum Zitat Pak CY, Sakhaee K, Gallagher C, et al. Attainment of therapeutic fluoride levels in serum without major side effects using a slow-release preparation of sodium fluoride in postmenopausal osteoporosis. J Bone Miner Res 1986; 1: 563–71PubMedCrossRef Pak CY, Sakhaee K, Gallagher C, et al. Attainment of therapeutic fluoride levels in serum without major side effects using a slow-release preparation of sodium fluoride in postmenopausal osteoporosis. J Bone Miner Res 1986; 1: 563–71PubMedCrossRef
150.
Zurück zum Zitat Gray TK, Brannan P, Juan D, et al. Ion transport changes during calcitonin-induced intestinal secretion in man. Gastroenterology 1976; 71: 392–8PubMed Gray TK, Brannan P, Juan D, et al. Ion transport changes during calcitonin-induced intestinal secretion in man. Gastroenterology 1976; 71: 392–8PubMed
151.
Zurück zum Zitat Zorzin L, Capone M. Postmenopausal osteoporosis: therapeutic and side effects of different calcitonins. Curr Ther Res 1984; 36: 473–82 Zorzin L, Capone M. Postmenopausal osteoporosis: therapeutic and side effects of different calcitonins. Curr Ther Res 1984; 36: 473–82
152.
Zurück zum Zitat Luzzani M, Vidili MG, Rissotto R, et al. Disodium clodronate in the treatment of pain due to bone metastases. Int J Clin Pharm Res 1990; 10: 243–6 Luzzani M, Vidili MG, Rissotto R, et al. Disodium clodronate in the treatment of pain due to bone metastases. Int J Clin Pharm Res 1990; 10: 243–6
153.
Zurück zum Zitat Khairi MR, Altman RD, DeRosa GP, et al. Sodium etidronate in the treatment of Paget’s disease of bone. A study of longterm results. Ann Intern Med 1977; 87: 656–63PubMed Khairi MR, Altman RD, DeRosa GP, et al. Sodium etidronate in the treatment of Paget’s disease of bone. A study of longterm results. Ann Intern Med 1977; 87: 656–63PubMed
154.
Zurück zum Zitat Federlin KF, Mehlburger L, Hillebrand I, et al. The effect of two new glucosidase inhibitors on blood glucose in healthy volunteers and in type 2 diabetics. Acta Diabetol Lat 1987; 24: 213–21PubMedCrossRef Federlin KF, Mehlburger L, Hillebrand I, et al. The effect of two new glucosidase inhibitors on blood glucose in healthy volunteers and in type 2 diabetics. Acta Diabetol Lat 1987; 24: 213–21PubMedCrossRef
155.
Zurück zum Zitat Hollander P. Safety profile of acarbose, an alpha-glucosidase inhibitor. Drugs 1992; 44Suppl. 2: 47–53PubMedCrossRef Hollander P. Safety profile of acarbose, an alpha-glucosidase inhibitor. Drugs 1992; 44Suppl. 2: 47–53PubMedCrossRef
156.
Zurück zum Zitat Johnston PS, Feig PU, Coniff RF, et al. Long-term titrated-dose alpha-glucosidase inhibitor in non-insulin-requiring Hispanic NIDDM patients. diabetes Care 1998; 21: 409–15PubMedCrossRef Johnston PS, Feig PU, Coniff RF, et al. Long-term titrated-dose alpha-glucosidase inhibitor in non-insulin-requiring Hispanic NIDDM patients. diabetes Care 1998; 21: 409–15PubMedCrossRef
157.
Zurück zum Zitat Melchior WR, Jaber LA. Metformin: an antihyperglycemic agent for treatment of type 2 diabetes. Ann Pharmacother 1996; 30: 158–64PubMed Melchior WR, Jaber LA. Metformin: an antihyperglycemic agent for treatment of type 2 diabetes. Ann Pharmacother 1996; 30: 158–64PubMed
158.
Zurück zum Zitat McGuinness ME, Talbert RL. Phenformin-induced lactic acidosis: a forgotten adverse drug reaction. Ann Pharmacother 1993; 27: 1183–7PubMed McGuinness ME, Talbert RL. Phenformin-induced lactic acidosis: a forgotten adverse drug reaction. Ann Pharmacother 1993; 27: 1183–7PubMed
159.
Zurück zum Zitat Curry CE, Tatum-Butler D. Laxative products. In: Covington TR, editor. Handbook of nonprescription drugs, 10th ed. Washington, DC: American Pharmaceutical Association, 1993: 219–33 Curry CE, Tatum-Butler D. Laxative products. In: Covington TR, editor. Handbook of nonprescription drugs, 10th ed. Washington, DC: American Pharmaceutical Association, 1993: 219–33
160.
Zurück zum Zitat Chusid MJ, Chusid JA. Diarrhea induced by sorbitol. J Pediatr 1981; 99: 326PubMed Chusid MJ, Chusid JA. Diarrhea induced by sorbitol. J Pediatr 1981; 99: 326PubMed
161.
Zurück zum Zitat Hammer HF, Santa Ana CA, Schiller LR, et al. Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethylene glycol and lactulose. J Clin Invest 1989; 84: 1056–62PubMedCrossRef Hammer HF, Santa Ana CA, Schiller LR, et al. Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethylene glycol and lactulose. J Clin Invest 1989; 84: 1056–62PubMedCrossRef
162.
Zurück zum Zitat Reele SB, Chodos DJ. Sorbitol induced diarrheal illness model. Int J Clin Pharmacol Ther Toxicol 1985; 23: 403–5PubMed Reele SB, Chodos DJ. Sorbitol induced diarrheal illness model. Int J Clin Pharmacol Ther Toxicol 1985; 23: 403–5PubMed
163.
Zurück zum Zitat Strom M. Antacid side-effects on bowel habits. Scand J Gastroenterol 1982; 17Suppl. 75: 54–5 Strom M. Antacid side-effects on bowel habits. Scand J Gastroenterol 1982; 17Suppl. 75: 54–5
164.
Zurück zum Zitat Anonymous. Senna and pseudomelanosis coli. Pharmacology 1992; 44 Suppl. 1:33–5 Anonymous. Senna and pseudomelanosis coli. Pharmacology 1992; 44 Suppl. 1:33–5
165.
Zurück zum Zitat Nataf C, Desmazures C, Giraudeaux V, et al. Laxative-induced intestinal protein loss in normal subjects. Gastroenterol Clin Biol 1981; 5: 187–92PubMed Nataf C, Desmazures C, Giraudeaux V, et al. Laxative-induced intestinal protein loss in normal subjects. Gastroenterol Clin Biol 1981; 5: 187–92PubMed
166.
Zurück zum Zitat Scheurlen C, Allgayer H, Kruis W, et al. Effect of olsalazine and mesalazine on human ileal and colonic (Na+/K+)-ATPase. A possible diarrhogenic factor? Clin Invest 1993; 71: 286–9CrossRef Scheurlen C, Allgayer H, Kruis W, et al. Effect of olsalazine and mesalazine on human ileal and colonic (Na+/K+)-ATPase. A possible diarrhogenic factor? Clin Invest 1993; 71: 286–9CrossRef
167.
Zurück zum Zitat Wright JP, O’Keefe EA, Cuming L, et al. Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Dig Dis Sci 1993; 38: 1837–42PubMedCrossRef Wright JP, O’Keefe EA, Cuming L, et al. Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Dig Dis Sci 1993; 38: 1837–42PubMedCrossRef
168.
Zurück zum Zitat Chawla A, Karl PI, Reich RN, et al. Effect of olsalazine on sodium-dependent bile acid transport in rat ileum. Dig Dis Sci 1995; 40: 943–8PubMedCrossRef Chawla A, Karl PI, Reich RN, et al. Effect of olsalazine on sodium-dependent bile acid transport in rat ileum. Dig Dis Sci 1995; 40: 943–8PubMedCrossRef
169.
Zurück zum Zitat Pamukcu R, Hanauer SB, Chang EB. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid. Gastroenterology 1988; 95: 975–81PubMed Pamukcu R, Hanauer SB, Chang EB. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid. Gastroenterology 1988; 95: 975–81PubMed
170.
Zurück zum Zitat Travis SP, Tysk C, de Silva HJ, et al. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 1994; 35: 1282–6PubMedCrossRef Travis SP, Tysk C, de Silva HJ, et al. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 1994; 35: 1282–6PubMedCrossRef
171.
Zurück zum Zitat Martenson JA, Hyland G, Moertel CG, et al. Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial. Int J Radiat Oncol Biol Phys 1996; 35: 299–303PubMedCrossRef Martenson JA, Hyland G, Moertel CG, et al. Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial. Int J Radiat Oncol Biol Phys 1996; 35: 299–303PubMedCrossRef
172.
Zurück zum Zitat Raimundo AH, Patil DH, Frost PG, et al. Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects. Gut 1991; 32: 270–74PubMedCrossRef Raimundo AH, Patil DH, Frost PG, et al. Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects. Gut 1991; 32: 270–74PubMedCrossRef
173.
Zurück zum Zitat Kruis W, Judmaier G, Kayasseh L, et al. Double-blind dosefinding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. Eur J Gastroenterol Hepatol 1995; 7: 391–6PubMed Kruis W, Judmaier G, Kayasseh L, et al. Double-blind dosefinding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. Eur J Gastroenterol Hepatol 1995; 7: 391–6PubMed
174.
Zurück zum Zitat Nilsson A, Danielsson A, Lofberg R, et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. Am J Gastroenterol 1995; 90: 381–7PubMed Nilsson A, Danielsson A, Lofberg R, et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. Am J Gastroenterol 1995; 90: 381–7PubMed
175.
Zurück zum Zitat Van Gaal LF, Broom JI, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Clin Pharmacol 1998; 54: 125–32PubMedCrossRef Van Gaal LF, Broom JI, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Clin Pharmacol 1998; 54: 125–32PubMedCrossRef
176.
Zurück zum Zitat Sjôstrôm L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167–73PubMedCrossRef Sjôstrôm L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167–73PubMedCrossRef
178.
Zurück zum Zitat Bow EJ, Gallant GJ, Woloschuk D, et al. Remission induction therapy of untreated acute myeloid leukemia using a noncytarabine-containing regimen of idarubicin, etoposide, and carboplatin. Cancer 1998; 83: 1344–54PubMedCrossRef Bow EJ, Gallant GJ, Woloschuk D, et al. Remission induction therapy of untreated acute myeloid leukemia using a noncytarabine-containing regimen of idarubicin, etoposide, and carboplatin. Cancer 1998; 83: 1344–54PubMedCrossRef
179.
Zurück zum Zitat Cascinu S, Fedeli A, Fedeli SL, et al. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 1993; 11: 148–51PubMed Cascinu S, Fedeli A, Fedeli SL, et al. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 1993; 11: 148–51PubMed
180.
Zurück zum Zitat Jarvis B, Shevchuk YM. Recurrent Clostridium difficile diarrhea associated with mitoxantrone and etoposide: a case report and review. Pharmacotherapy 1997; 17: 606–11PubMed Jarvis B, Shevchuk YM. Recurrent Clostridium difficile diarrhea associated with mitoxantrone and etoposide: a case report and review. Pharmacotherapy 1997; 17: 606–11PubMed
181.
Zurück zum Zitat Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993; 17: 109–13PubMedCrossRef Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993; 17: 109–13PubMedCrossRef
182.
Zurück zum Zitat Husain A, Aptaker L, Spriggs DR, et al. Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecol Oncol 1998: 71: 104–7PubMedCrossRef Husain A, Aptaker L, Spriggs DR, et al. Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecol Oncol 1998: 71: 104–7PubMedCrossRef
183.
Zurück zum Zitat Cudmore MA, Silva J, Fekety R, et al. Clostridium difficile colitis associated with cancer chemotherapy. Arch Intern Med 1982; 142: 333–5PubMed Cudmore MA, Silva J, Fekety R, et al. Clostridium difficile colitis associated with cancer chemotherapy. Arch Intern Med 1982; 142: 333–5PubMed
184.
Zurück zum Zitat Jackson IM, Barnard LB, Lamberton P. Role of a long-acting somatostatin analogue (SMS 201-995) in the treatment of acromegaly. Am J Med 1986; 81: 94–101PubMedCrossRef Jackson IM, Barnard LB, Lamberton P. Role of a long-acting somatostatin analogue (SMS 201-995) in the treatment of acromegaly. Am J Med 1986; 81: 94–101PubMedCrossRef
185.
Zurück zum Zitat Ho PJ, Boyaji LD, Greenstein E, et al. Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly. Dig Dis Sci 1993; 38: 309–15PubMedCrossRef Ho PJ, Boyaji LD, Greenstein E, et al. Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly. Dig Dis Sci 1993; 38: 309–15PubMedCrossRef
186.
Zurück zum Zitat Nakamura T, Kudoh K, Takebe K, et al. Octreotide decreases biliary and pancreatic exocrine function, and induces steatorrhea in healthy subjects. Intern Med 1994; 33: 593–6PubMedCrossRef Nakamura T, Kudoh K, Takebe K, et al. Octreotide decreases biliary and pancreatic exocrine function, and induces steatorrhea in healthy subjects. Intern Med 1994; 33: 593–6PubMedCrossRef
187.
Zurück zum Zitat Kuhn JM, Legrand A, Ruiz JM, et al. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmacol 1994; 38: 213–9PubMedCrossRef Kuhn JM, Legrand A, Ruiz JM, et al. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmacol 1994; 38: 213–9PubMedCrossRef
188.
Zurück zum Zitat Maton PN, Iser JH, Reuben A, et al. Outcome of chenodeoxycholic acid (CDCA) treatment in 125 patients with radiolucent gallstones. Medicine 1982; 61: 86–97PubMedCrossRef Maton PN, Iser JH, Reuben A, et al. Outcome of chenodeoxycholic acid (CDCA) treatment in 125 patients with radiolucent gallstones. Medicine 1982; 61: 86–97PubMedCrossRef
189.
Zurück zum Zitat Kruis W, Haddad A, Phillips SF. Chenodeoxycholic and ursodeoxycholic acids alter motility and fluid transit in the canine ileum. Digestion 1986; 34: 185–95PubMedCrossRef Kruis W, Haddad A, Phillips SF. Chenodeoxycholic and ursodeoxycholic acids alter motility and fluid transit in the canine ileum. Digestion 1986; 34: 185–95PubMedCrossRef
190.
Zurück zum Zitat Sackmann M, Paulezki J, Aydemir U, et al. Efficacy and safety of ursodeoxycholic acid for dissolution of gallstone fragments: comparison with the combination of ursodeoxycholic acid and chenodeoxycholic acid. Hepatology 1991; 14: 1136–41PubMed Sackmann M, Paulezki J, Aydemir U, et al. Efficacy and safety of ursodeoxycholic acid for dissolution of gallstone fragments: comparison with the combination of ursodeoxycholic acid and chenodeoxycholic acid. Hepatology 1991; 14: 1136–41PubMed
191.
Zurück zum Zitat Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol 1987; 2: 10–32PubMed Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol 1987; 2: 10–32PubMed
192.
Zurück zum Zitat Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997; 17: 208–21PubMedCrossRef Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997; 17: 208–21PubMedCrossRef
193.
Zurück zum Zitat Gracon SI, Knapp MJ, Berghoff WG, et al. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis Assoc Disord 1998; 12: 93–101PubMedCrossRef Gracon SI, Knapp MJ, Berghoff WG, et al. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis Assoc Disord 1998; 12: 93–101PubMedCrossRef
194.
Zurück zum Zitat Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil study group. Arch Intern Med 1998; 158: 1021–31PubMedCrossRef Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil study group. Arch Intern Med 1998; 158: 1021–31PubMedCrossRef
195.
Zurück zum Zitat Antuono PG. Effectiveness and safety of velnacrine for the treatment of Alzheimer’s disease. A double-blind, placebo-controlled study. Mentane study group. Arch Intern Med 1995; 155: 1766–72PubMedCrossRef Antuono PG. Effectiveness and safety of velnacrine for the treatment of Alzheimer’s disease. A double-blind, placebo-controlled study. Mentane study group. Arch Intern Med 1995; 155: 1766–72PubMedCrossRef
196.
Zurück zum Zitat Bever KA, Perrry PJ. Dexfenfluramine hydrochloride: an anorexigenic agent. Am J Health Syst Pharm 1997; 54: 2059–72PubMed Bever KA, Perrry PJ. Dexfenfluramine hydrochloride: an anorexigenic agent. Am J Health Syst Pharm 1997; 54: 2059–72PubMed
197.
Zurück zum Zitat Wagner ML, Landis BE. Riluzole: a new agent for amyotrophic lateral sclerosis. Ann Pharmacother 1997; 31: 738–44PubMed Wagner ML, Landis BE. Riluzole: a new agent for amyotrophic lateral sclerosis. Ann Pharmacother 1997; 31: 738–44PubMed
198.
Zurück zum Zitat Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson’s disease: efficacy and safety of long-term treatment. Tolcapone stable study group. Neurology 1998; 50Suppl. 5: 39–45CrossRef Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson’s disease: efficacy and safety of long-term treatment. Tolcapone stable study group. Neurology 1998; 50Suppl. 5: 39–45CrossRef
199.
Zurück zum Zitat Labayle D, Delas N, Pariente A, et al. Severe psychiatric disorders associated with severe acute colitis. Gastroenterol Clin Biol 1992; 16: 639–43PubMed Labayle D, Delas N, Pariente A, et al. Severe psychiatric disorders associated with severe acute colitis. Gastroenterol Clin Biol 1992; 16: 639–43PubMed
200.
Zurück zum Zitat Basse P. Ischemic colitis complicating imipramine overdose and alcohol ingestion. Eur J Surg 1992; 158: 187–8PubMed Basse P. Ischemic colitis complicating imipramine overdose and alcohol ingestion. Eur J Surg 1992; 158: 187–8PubMed
201.
Zurück zum Zitat Meya U, Moller B, Renfordt E, et al. A case of perazine-induced enteritis. Allergy or pseudoallergy? Pharmacopsychiatry 1985; 18: 263–6PubMedCrossRef Meya U, Moller B, Renfordt E, et al. A case of perazine-induced enteritis. Allergy or pseudoallergy? Pharmacopsychiatry 1985; 18: 263–6PubMedCrossRef
202.
Zurück zum Zitat Mahajan L, Wyllie R, Goldblum J. Lymphocytic colitis in a pediatric patient: a possible adverse reaction to carbamazepine. Am J Gastroenterol 1997; 92: 2126–7PubMed Mahajan L, Wyllie R, Goldblum J. Lymphocytic colitis in a pediatric patient: a possible adverse reaction to carbamazepine. Am J Gastroenterol 1997; 92: 2126–7PubMed
203.
Zurück zum Zitat Chauveau E, Prignet JM, Carloz E, et al. Lymphocytic colitis secondary to ingestion of vinburnine (Cervoxan). Gastroenterol Clin Biol 1998; 22: 362PubMed Chauveau E, Prignet JM, Carloz E, et al. Lymphocytic colitis secondary to ingestion of vinburnine (Cervoxan). Gastroenterol Clin Biol 1998; 22: 362PubMed
204.
Zurück zum Zitat Martin P, Manley PN, Depew WT, et al. Isotretinoin-associated proctosigmoiditis. Gastroenterology 1987; 93: 606–9PubMed Martin P, Manley PN, Depew WT, et al. Isotretinoin-associated proctosigmoiditis. Gastroenterology 1987; 93: 606–9PubMed
205.
Zurück zum Zitat Cox J, Daneshmend TK, Hawkey CJ, et al. Devastating diarrhea caused by azathioprine: management difficulty in inflammatory bowel disease. Gut 1988; 29: 686–8PubMedCrossRef Cox J, Daneshmend TK, Hawkey CJ, et al. Devastating diarrhea caused by azathioprine: management difficulty in inflammatory bowel disease. Gut 1988; 29: 686–8PubMedCrossRef
206.
Zurück zum Zitat Murphy EA, Morris AJ, Walker E, et al. Cyclosporine Ainduced colitis and acquired selective IgA deficiency in a patient with juvenile chronic arthritis. J Rheumatol 1993; 20: 1397–8PubMed Murphy EA, Morris AJ, Walker E, et al. Cyclosporine Ainduced colitis and acquired selective IgA deficiency in a patient with juvenile chronic arthritis. J Rheumatol 1993; 20: 1397–8PubMed
208.
Zurück zum Zitat Pike IM, Nicaise C. The didanosine expanded access program: safety analysis. Clin Infect Dis 1993; 16Suppl. 1: 63–8CrossRef Pike IM, Nicaise C. The didanosine expanded access program: safety analysis. Clin Infect Dis 1993; 16Suppl. 1: 63–8CrossRef
209.
Zurück zum Zitat Lieb J, Kazienko DJ. Lactose filler as a cause of ‘drug-induced’ diarrhea. N Engl J Med 1978; 299: 314PubMed Lieb J, Kazienko DJ. Lactose filler as a cause of ‘drug-induced’ diarrhea. N Engl J Med 1978; 299: 314PubMed
210.
Zurück zum Zitat Shelly MS. Iatrogenic diarrhea caused by sorbitol. J Fam Pract 1993; 36: 95–6PubMed Shelly MS. Iatrogenic diarrhea caused by sorbitol. J Fam Pract 1993; 36: 95–6PubMed
211.
Zurück zum Zitat Hill DB, Henderson LM, McClain CJ. Osmotic diarrhea induced by sugar-free theophylline solution in critically ill patients. J Parenter Enterol Nutr 1991; 15: 332–6CrossRef Hill DB, Henderson LM, McClain CJ. Osmotic diarrhea induced by sugar-free theophylline solution in critically ill patients. J Parenter Enterol Nutr 1991; 15: 332–6CrossRef
212.
Zurück zum Zitat Spreux A, Rodriguez A, Chichmanian RM. Case reports on drug-induced chronic diarrhea. An often unrecognized etiology? Therapie 1993; 48: 494–5PubMed Spreux A, Rodriguez A, Chichmanian RM. Case reports on drug-induced chronic diarrhea. An often unrecognized etiology? Therapie 1993; 48: 494–5PubMed
213.
Zurück zum Zitat Talal AH, Murray JA. Acute and chronic diarrhea. How to keep laboratory testing to a minimum. Postgrad Med 1994; 96: 30–8PubMed Talal AH, Murray JA. Acute and chronic diarrhea. How to keep laboratory testing to a minimum. Postgrad Med 1994; 96: 30–8PubMed
214.
Zurück zum Zitat Bennett RG, Greenough WB. Approach to acute diarrhea in the elderly. Gastroenterol Clin North Am 1993; 22: 517–33PubMed Bennett RG, Greenough WB. Approach to acute diarrhea in the elderly. Gastroenterol Clin North Am 1993; 22: 517–33PubMed
215.
Zurück zum Zitat Donowitz M, Kokke FT, Saidi R. Evaluation of patients with chronic diarrhea. N Engl J Med 1995; 332: 725–9PubMedCrossRef Donowitz M, Kokke FT, Saidi R. Evaluation of patients with chronic diarrhea. N Engl J Med 1995; 332: 725–9PubMedCrossRef
216.
Zurück zum Zitat Duncan A, Cameron A, Stewart MJ, et al. Diagnosis of the abuse of magnesium and stimulant laxatives. Ann Clin Biochem 1991; 28: 568–73PubMed Duncan A, Cameron A, Stewart MJ, et al. Diagnosis of the abuse of magnesium and stimulant laxatives. Ann Clin Biochem 1991; 28: 568–73PubMed
217.
Zurück zum Zitat Read NW, Krjs GJ, Read MG, et al. Chronic diarrhea of unknown origin. Gastroenterology 1980; 78: 264–71PubMed Read NW, Krjs GJ, Read MG, et al. Chronic diarrhea of unknown origin. Gastroenterology 1980; 78: 264–71PubMed
218.
Zurück zum Zitat Wenisch C, Parschalk B, Hasenhundl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22: 813–8PubMedCrossRef Wenisch C, Parschalk B, Hasenhundl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22: 813–8PubMedCrossRef
219.
Zurück zum Zitat Hospital Infection Control Advisory Committee. Recommendations for preventing the spread of vancomycin-resistant enterococci. Am J Infect Control 1995; 23: 87–94 Hospital Infection Control Advisory Committee. Recommendations for preventing the spread of vancomycin-resistant enterococci. Am J Infect Control 1995; 23: 87–94
220.
Zurück zum Zitat Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997; 24: 324–33PubMedCrossRef Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997; 24: 324–33PubMedCrossRef
221.
Zurück zum Zitat Lewis SJ, Freedman AR. Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther 1998; 12: 807–22PubMedCrossRef Lewis SJ, Freedman AR. Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther 1998; 12: 807–22PubMedCrossRef
222.
Zurück zum Zitat Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect 1998; 36: 171–4PubMedCrossRef Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect 1998; 36: 171–4PubMedCrossRef
223.
Zurück zum Zitat McFarland LV, Surawicz CM, Greenberg RN, et al. Arandomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 1913–8PubMedCrossRef McFarland LV, Surawicz CM, Greenberg RN, et al. Arandomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 1913–8PubMedCrossRef
224.
Zurück zum Zitat Fredenucci I, Chomarat M, Boucaud C, et al. Saccharomyces boulardii fungemia in a patient receiving Ultra-levure therapy. Clin Infect Dis 1998; 27: 222–3PubMedCrossRef Fredenucci I, Chomarat M, Boucaud C, et al. Saccharomyces boulardii fungemia in a patient receiving Ultra-levure therapy. Clin Infect Dis 1998; 27: 222–3PubMedCrossRef
225.
Zurück zum Zitat Viggiano M, Badetti C, Bernini V, et al. Saccharomyces boulardii fungemia in a patient with severe burns. Ann Fr Anesth Reanim 1995; 14: 356–8PubMedCrossRef Viggiano M, Badetti C, Bernini V, et al. Saccharomyces boulardii fungemia in a patient with severe burns. Ann Fr Anesth Reanim 1995; 14: 356–8PubMedCrossRef
226.
Zurück zum Zitat Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med 1998; 105: 71–2PubMedCrossRef Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med 1998; 105: 71–2PubMedCrossRef
227.
Zurück zum Zitat McCullough MJ, Clemons KV, McCusker JH, et al. Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.). J Clin Microbiol 1998; 36: 2613–7PubMed McCullough MJ, Clemons KV, McCusker JH, et al. Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.). J Clin Microbiol 1998; 36: 2613–7PubMed
Metadaten
Titel
Drug-Induced Diarrhoea
verfasst von
Dr Olivier Chassany
Alessandra Michaux
Jean François Bergmann
Publikationsdatum
01.01.2000
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 1/2000
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200022010-00005

Weitere Artikel der Ausgabe 1/2000

Drug Safety 1/2000 Zur Ausgabe